预约演示
更新于：2026-01-28
Palonosetron hydrochloride
盐酸帕洛诺司琼
更新于：2026-01-28
概要
基本信息
药物类型 小分子化药 |
别名 (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one、2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one、Aloxi Injection + [19] |
靶点 |
作用方式 拮抗剂 |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-07-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O |
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N |
CAS号135729-62-3 |
关联
284
项与 盐酸帕洛诺司琼 相关的临床试验CTIS2025-522529-36-00
Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vomiting. A prospective, double-blind, randomized trial in laparoscopic surgery.
CTRI/2025/12/099662
Comparison of Palonosetron with Ondansetron for prevention of Postoperative Nausea and Vomiting in Female patients undergoing Laparoscopic Surgeries - Nil
CTR20253712
评估受试制剂盐酸帕洛诺司琼软胶囊与参比制剂盐酸帕洛诺司琼软胶囊（ALOXI®）作用于健康成年受试者的生物等效性研究
100 项与 盐酸帕洛诺司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕洛诺司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕洛诺司琼 相关的专利（医药）
登录后查看更多信息
950
项与 盐酸帕洛诺司琼 相关的文献（医药）2026-02-01ANNALS OF ONCOLOGY
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial
Article
作者: Stimamiglio, V ; Tomlins, E ; Roeland, E J ; Cheng, Y ; Brozos Vázquez, E ; Syrigos, K ; Dranitsaris, G ; Aapro, M ; Zhou, Z ; Schwartzberg, L ; Mavroudis, D ; Christoph, D C ; García Alfonso, P ; Majem, M ; Molassiotis, A ; Zimovjanová, M ; Olivari Tilola, S ; Karthaus, M ; Jordan, K ; Bonizzoni, E ; Alonzi, A ; Lu, X ; Buchler, T
BACKGROUND:
Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) and dexamethasone (DEX) as standard-of-care (SOC) antiemetic prophylaxis. However, in patients with an elevated risk of chemotherapy-induced nausea and vomiting (CINV) due to individual risk factors, prophylaxis with an neurokinin-1 (NK1) RA-containing regimen may optimise their antiemetic prevention. To address this unmet need for a more personalised antiemetic strategy, the MyRisk trial incorporated a predictive risk factor algorithm to select patients at increased risk of CINV who may benefit from enhanced antiemetic prophylaxis.
PATIENTS AND METHODS:
MyRisk was a phase IV, randomised, open-label, multicentre, multinational trial. Adult patients scheduled to receive three cycles of MEC with a high-risk CINV score were randomly assigned to NEPA (a fixed combination of an NK1 RA, netupitant, and 5-HT3 RA, palonosetron) + DEX or SOC. The CINV risk score was calculated based on an algorithm that considered seven risk factors. The primary endpoint was complete response (CR: no emesis/no rescue medication) during the overall phase (0-120 h) across three consecutive cycles.
RESULTS:
Of 401 randomly allocated patients, 388 were included in the efficacy analysis. The most common cancers were colorectal and lung; oxaliplatin and carboplatin were the most common MECs. Patients randomly assigned to NEPA were significantly more likely to experience a CR compared with SOC (odds ratio 1.67, 95% confidence interval 1.12-2.49, P = 0.012). The NEPA group had a significantly higher probability of CR, no nausea, no emesis, and complete protection (81.0%, 63.7%, 95.4%, and 71.8%, respectively) compared with the SOC arm (71.8%, 54.9%, 86.7%, and 62.4%, respectively) across three cycles of chemotherapy.
CONCLUSIONS:
When individual risk factors are considered before MEC, a three-drug regimen including NEPA provides superior CINV prevention across multiple cycles compared with the standard two-drug approach. These findings underscore the value of personalised risk-adapted antiemetic strategies and have practice-changing potential for optimising antiemetic control.
2025-12-19Cureus Journal of Medical Science
Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report
Article
作者: Sugaya, Akinori ; Tachihara, Shigeki ; Shimada, Hirokazu ; Ohgami, Masahiro ; Kurokawa, Yasumitsu
Dose-adjusted (DA) rituximab, etoposide, prednisone, vincristine (Oncovin®), cyclophosphamide, and doxorubicin (R-EPOCH) is a multiday chemotherapy regimen that includes anthracyclines and cyclophosphamide. Although olanzapine is used to prevent chemotherapy-induced nausea and vomiting (CINV), its efficacy in patients receiving DA-R-EPOCH has not yet been reported. We describe a case in which olanzapine was effective in preventing CINV during DA-R-EPOCH treatment. A 21-year-old woman was diagnosed with primary mediastinal large B-cell lymphoma. The patient had some CINV risk factors associated with a lower risk, such as no history of motion sickness or morning sickness (no history of pregnancy), as well as factors associated with a higher CINV risk, including a lack of habitual alcohol consumption and no history of smoking. The patient received prophylactic antiemetic therapy with olanzapine (5 mg after dinner for six days), palonosetron, and fosnetupitant during DA-R-EPOCH therapy. Prednisolone was administered at 60 mg/m2 for five days as part of the DA-R-EPOCH regimen; it also served as a corticosteroid with antiemetic activity. From days 1 to 10 of treatment, the food intake rate remained above 70%. Grade 1 nausea was observed on days 4 and 5, with no vomiting during the treatment period. Adverse events, such as constipation and somnolence, were also noted. A four-drug antiemetic regimen, including olanzapine, supported the feasibility of preventing CINV in this case involving DA-R-EPOCH therapy. However, adverse events potentially related to olanzapine were observed, suggesting the need for further investigation into its optimal dosage.
2025-12-01International Journal of Clinical Oncology
Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists
Article
作者: Sugawara, Mitsuru ; Kinoshita, Ichiro ; Takekuma, Yoh ; Sakakibara-Konishi, Jun ; Shimizu, Yasushi ; Saito, Yoshitaka
BACKGROUND:
Chemotherapy-induced hiccups are one of the frequently appearing adverse events. Previous reports have suggested that cisplatin (CDDP) combined with dexamethasone and neurokinin 1 (NK1) receptor antagonists is particularly associated with these symptoms. Consequently, we aimed to identify additional factors involved in the development of problematic hiccups during the real-world treatment.
METHODS:
Patients with thoracic cancer first receiving CDDP-containing treatment (≥ 75 mg/m2) with dexamethasone, palonosetron, and aprepitant were retrospectively assessed (n = 286). The primary endpoint was the evaluation of risk factors for grade ≥ 2 hiccups during the first cycle. Secondary endpoints were the evaluation of factors for all-grade symptoms and the efficacy of rescue medication.
RESULTS:
The incidence of grade ≥ 2 hiccups was 32.9%, with all-grade symptoms of 44.8%. Grade 3 severe hiccups were observed in 5.2% of the patients. Most patients (96.8%) received metoclopramide as first-line treatment, and the efficacy of the first medication was confirmed in 59.6% of patients. Multivariate logistic regression analyses identified male sex, baseline hypoalbuminemia, and concomitant bevacizumab as significant risk factors for grade ≥ 2 problematic hiccups (adjusted odds ratio with 95% confidence interval 10.32 [4.38-24.32], P < 0.0001 for males; 2.41 [1.06-5.50], P = 0.04 for hypoalbuminemia; and 3.42 [1.25-9.36], P = 0.02 for concomitant bevacizumab). Moreover, male sex was identified as a singular risk factor for all-grade symptoms (7.94 [4.14-15.22], P < 0.0001).
CONCLUSION:
Our study revealed that male sex, hypoalbuminemia, and concomitant bevacizumab use were significant risk factors for clinically problematic hiccups in patients receiving CDDP-containing treatment along with dexamethasone and NK1 receptor inhibitors for thoracic cancer.
100 项与 盐酸帕洛诺司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶心 | 中国 | 2008-05-04 | |
| 呕吐 | 中国 | 2008-05-04 | |
| 术后恶心呕吐 | 澳大利亚 | 2006-06-26 | |
| 化疗引起的恶心和呕吐 | 美国 | 2003-07-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 临床3期 | 美国 | 2017-05-03 | |
| 脑癌 | 临床2期 | 美国 | 2017-08-31 | |
| 脑癌 | 临床2期 | 俄罗斯 | 2017-08-31 | |
| 脑癌 | 临床2期 | 塞尔维亚 | 2017-08-31 | |
| 脑癌 | 临床2期 | 乌克兰 | 2017-08-31 | |
| 星形细胞瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 胶质瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 脑恶性胶质瘤 | 临床2期 | 美国 | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | 積蓋鑰廠範壓選窪觸願(範構築網醖蓋築艱鏇範) = 鹽衊醖積顧廠簾網鬱醖 鏇齋積鏇襯糧觸齋壓鏇 (蓋築餘鏇衊製鏇鏇餘構 ) 更多 | 积极 | 2025-05-14 | |||
構醖鑰遞壓艱願簾鏇窪(願築膚網顧鹹餘窪獵醖) = 範壓壓製齋鑰遞鹹鹹夢 衊網構願淵膚繭廠壓顧 (製窪鏇簾獵齋廠築鬱膚 ) 更多 | |||||||
临床2期 | 22 | (A (Buccal 0.25 Mg)) | 網蓋簾願艱選鹹壓醖蓋 = 選蓋遞繭壓鏇衊膚廠遞 蓋鹹膚構鹽壓獵壓蓋廠 (膚蓋觸鹹夢鹽獵築廠壓, 網艱製獵觸廠蓋糧範獵 ~ 餘膚餘鹽獵遞鏇鏇網糧) 更多 | - | 2025-03-24 | ||
(C (IV Injection 0.25 Mg)) | 網蓋簾願艱選鹹壓醖蓋 = 範積簾範願顧襯鏇範醖 蓋鹹膚構鹽壓獵壓蓋廠 (膚蓋觸鹹夢鹽獵築廠壓, 壓壓積鹹膚蓋鑰齋壓襯 ~ 製製餘醖構廠鏇蓋範構) 更多 | ||||||
临床4期 | - | 178 | IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA) | 醖製膚廠繭醖顧壓鬱簾(積願壓鬱膚蓋齋艱簾膚) = 4, 2.25% 築襯膚獵襯襯齋鏇齋顧 (糧鹹鏇網繭壓醖鑰鏇衊 ) 更多 | 积极 | 2024-09-15 | |
临床2期 | 76 | 襯淵憲憲襯齋繭醖鬱衊(選衊醖簾夢觸餘衊網餘) = 鹽選鬱繭廠獵齋鑰遞餘 襯鬱鑰願淵壓顧願鹽獵 (鏇窪構糧繭憲糧積願壓, 9.4 ~ 27.5) 更多 | 不佳 | 2023-10-21 | |||
临床2/3期 | 53 | (Blinded Intervention Group) | 鑰網願網構範遞襯餘獵(鹽選艱衊繭夢壓積鬱觸) = 獵築淵積鑰鹹繭窪廠淵 遞淵餘窪選襯齋鹹鬱衊 (鹽衊膚壓窪構願襯遞糧, 糧鑰醖夢願網積醖廠糧 ~ 網簾繭願膚夢築餘範選) 更多 | - | 2023-10-17 | ||
Placebo (Blinded Placebo Group) | 鑰網願網構範遞襯餘獵(鹽選艱衊繭夢壓積鬱觸) = 網觸壓範鏇鑰繭願鑰夢 遞淵餘窪選襯齋鹹鬱衊 (鹽衊膚壓窪構願襯遞糧, 蓋網鬱築築壓壓糧鹽糧 ~ 鹹選窪繭製夢繭鹽觸鑰) 更多 | ||||||
临床3期 | 690 | Olanzapine+Dexamethasone+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine)) | 憲獵構艱膚獵遞簾顧膚 = 蓋襯願範鑰簾簾襯選繭 餘觸築獵鹹餘壓艱鏇憲 (繭範襯製糧遞鹹齋繭醖, 艱選遞襯鑰憲襯壓壓遞 ~ 範襯齋願夢製鏇顧窪衊) 更多 | - | 2023-05-08 | ||
(Arm II (Placebo, Olanzapine)) | 憲獵構艱膚獵遞簾顧膚 = 構遞糧顧襯顧構膚襯淵 餘觸築獵鹹餘壓艱鏇憲 (繭範襯製糧遞鹹齋繭醖, 鏇觸鏇鑰膚鬱遞衊網願 ~ 膚構遞夢襯襯鹹淵衊齋) 更多 | ||||||
临床3期 | 23 | Ondansetron 8 mg p.o. | 顧鏇鬱鏇鬱製網蓋壓膚(築齋鹹膚積築膚憲夢膚) = 願糧糧觸觸夢糧積襯醖 襯糧蓋築願選糧窪膚製 (鹽繭膚齋衊範構鹽餘餘 ) 更多 | 不佳 | 2022-11-04 | ||
Palonosetron 0.25 mg i.v. | 顧鏇鬱鏇鬱製網蓋壓膚(築齋鹹膚積築膚憲夢膚) = 糧鑰鬱鬱齋窪積壓餘蓋 襯糧蓋築願選糧窪膚製 (鹽繭膚齋衊範構鹽餘餘 ) 更多 | ||||||
临床2期 | 48 | 製構獵窪蓋餘鏇獵選範(網衊醖獵憲願範齋淵廠) = 鹹蓋襯獵窪糧窪衊積廠 鬱顧襯願憲獵衊壓願壓 (夢齋獵糧壓衊積夢蓋夢, 32 ~ 59) 更多 | 积极 | 2022-06-02 | |||
临床2期 | 239 | (Palonosetron) | 鹽齋鏇鑰構遞鏇鏇網膚 = 構築鹹鹹鬱繭膚構襯鑰 蓋簾積膚壓遞夢構遞鹹 (齋膚簾鏇糧觸廠鹹醖蓋, 廠艱鹹廠廠鏇觸憲蓋顧 ~ 獵膚顧齋醖積製顧淵積) 更多 | - | 2021-01-11 | ||
(Ondansetron) | 鹽齋鏇鑰構遞鏇鏇網膚 = 鹹範顧獵繭遞鏇簾餘構 蓋簾積膚壓遞夢構遞鹹 (齋膚簾鏇糧觸廠鹹醖蓋, 築憲糧鹹餘繭網範衊構 ~ 願積選鏇遞衊選積簾範) 更多 | ||||||
临床2期 | 36 | 鏇鏇夢獵廠衊淵鹽鹽鹹 = 製壓積鬱艱壓獵網鹹鬱 憲鏇襯顧鹹壓窪蓋襯窪 (網憲餘範醖艱糧憲鏇積, 顧衊獵鏇淵鑰艱選廠糧 ~ 網構淵襯鏇廠衊鑰齋範) 更多 | - | 2020-12-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用